ABOUT US

Global Leader of Cancer Treatments

History

img of buillding
  • 2020
    May.

    ATB-410, R&D grant (Ministry of SMEs and Startups)

    Apr.

    ATB-301, R&D grant (Ministry of Trade, Industry and Energy)

    AzothBio-AutotelicBio, Co-development agreement for targeted anticancer therapy

    Jan.

    Technology Innovation-Oriented Small and Medium Enterprise(Inno-Biz), (Ministry of SMEs and Startups)

  • 2019
    Dec.

    Series A round with Mega Investment & UTC Investment

    ATB-310 R&D grant (INNOPOLIS Foundation)

    Nov.

    Immuno-oncology R&D grant (Medical Innovation Foundation)

    Oct.

    Investment agreement with Aju Pharm & KODIT

    Sep.

    Expansion & new location of Pankyo R&D center

    Jun.

    ATB-101, “K-Startup” R&D grant (Ministry of SMEs and Startups)

    Licensed-in K284-6111, the new generation oncology targeted therapy candidate

    May.

    TASO CMO agreement with ST Pharm

    Apr.

    ATB-301 selected in “Pharm Navi” project by MFDS (such as “Fast Track” regulation system in US FDA)

    Jan.

    ATB-101 Tech Transfer and Investment agreement with Jeil Pharm.

  • 2018
    Sep.

    Pankyo R&D center Establishment

    Aug.

    Angel Investment

    Jul.

    Investment agreement with TIPS

    Feb.

    Venture designation (Korea Technology Finance Corporation)

    Jan.

    Company name change to Autotelic Bio

  • 2017
    Sep.

    ATB-101 Government R&D grant(Ministry of SMEs and Startups)

    Corporate R&D center accreditation

  • 2015
    Nov.

    Autotelic Korea Establishment (Foreign investment company)